henry j fuchs chief medical officer biomarin pharmaceutical timesjavascript is disabled market profiles login sign up login sign up   edit person henry j fuchs chief medical officer at biomarin pharmaceutical location san francisco bay area add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop henry j fuchs chief medical officer at biomarin pharmaceutical location san francisco bay area add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop enry j fuchs md has served as a director of genomic health since september  dr fuchs is the executive vice president and chief medical officer of biomarin pharmaceutical inc a biopharmaceutical company from september  to december  dr fuchs was executive vice president and chief medical officer of onyx pharmaceuticals inc a biopharmaceutical company from october  until june  dr fuchs served in multiple roles of increasing responsibility at ardea biosciences inc a biotechnology company first as vice president clinical affairs then as president and chief operating officer and finally as president and chief executive officer from  to  dr fuchs held various positions at genentech inc a biotechnology company dr fuchs serves as a director of mirati therapeutics inc and served as a director of ardea biosciences inc from november  to june  dr fuchs received a ba in biochemical sciences from harvard university and an md from george washington university  companies in career na related markets  colleagues na related investments alias na industry rd in biotech environmental and various industries no marketing product yet tags na topics of influence na na careers achievements investments related people edit view all henry j fuchscareer  aug genomic health board member feb mirati board member mar biomarin pharmaceutical chief medical officer oct to nov onyx pharmaceuticals chief medical officer oct to may intrabiotics chief medical officer nov to oct genentech senior director competencies edit view all henry j fuchseducation   the george washington university school of medicine and health sciences  harvard university biochemical sciences edit henry j fuchsachievements and recognitions add milestone no milestones has been recorded for henry j fuchs edit henry j fuchslinks add link no links has been recorded for henry j fuchs henry j fuchsinvestmentsacquisitions no investments has been recorded for henry j fuchs henry j fuchsinvestments representing others no investment reps has been recorded for henry j fuchs henry j fuchsrelated people colleagues at biomarin pharmaceutical richard ranieri svp human resources and corporate affairs  chito hernandez vice president biometrics may jeff ajer evp chief commercial officer sep dan spiegelman evp  cfo may view all henry j fuchsrecommended market profiles  telemedicine  or more employees  companies social media marketing chiefmarteccom    employees  companies big data universe list of lists  or more employees  companies aggregated marketing technology  or more employees  companies shared economy landscape jeremiah owyang  or more employees  companies inside sales landscape  or more employees  companies henry fuchs  biomarin pharmaceutical inc  zoominfocom insider trading  fuchs henry j  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  fuchs henry j select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing sale  pm biomarin pharmaceutical inc bmrn fuchs henry jpresident worldwide rd    direct view sale  pm biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer    direct view sale  pm biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer    direct view sale  pm biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer    direct view sale  pm biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer    direct view sale  pm biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer    direct view sale  pm biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer    direct view sale  pm biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer    direct view sale  pm biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer    direct view salea  pm biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer    direct view a indicate amendment filing stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm nana genomic health inc ghdx fuchs henry jdirector   direct view exercise  pm nana biomarin pharmaceutical inc bmrn fuchs henry jpresident worldwide rd   direct view exercise  pm  biomarin pharmaceutical inc bmrn fuchs henry jpresident worldwide rd   direct view option award  pm nana genomic health inc ghdx fuchs henry jdirector   direct view exercise  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view exercise  pm  biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view option award  pm nana genomic health inc ghdx fuchs henry jdirector   direct view option award  pm  genomic health inc ghdx fuchs henry jdirector   direct view tax withholding  am nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view exercise  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view exercise  pm  biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view option award  pm na mirati therapeutics inc mrtx fuchs henry jdirector   direct view tax withholding  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view option award  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view tax withholding  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view option award  pm nana genomic health inc ghdx fuchs henry jdirector   direct view option award  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view option award  pm  biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view tax withholding  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view tax withholding  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view option award  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view option award  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view option award  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view option award  pm nana genomic health inc ghdx fuchs henry jdirector   direct view option award  pm nana genomic health inc ghdx fuchs henry jdirector   direct view option award  pm nana genomic health inc ghdx fuchs henry jdirector   direct view option award  pm  genomic health inc ghdx fuchs henry jdirector   direct view tax withholding  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view option award  pm na mirati therapeutics inc mrtx fuchs henry jdirector   direct view tax withholding  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view tax withholding  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view tax withholding  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view option award  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view option award  pm nana genomic health inc ghdx fuchs henry jdirector   direct view exercise  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view exercise  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view exercise  pm  biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view exercise  pm  biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view option award  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view option award  pm  biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view tax withholding  pm nana biomarin pharmaceutical inc bmrn fuchs henry jevp chief medical officer   direct view   secformcom all rights reserved archives        mon  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  form  biomarin pharmaceutical for jun  filed by fuchs henry j research stocks news story skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  news  events  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print format change text size default text sizea larger text sizea largest text sizea form  biomarin pharmaceutical for jun  filed by fuchs henry j by k wizard—  pm et  httparchivefastedgarcomarzoczmvgakmsbswzcz filed on june   more bmrn news briefbiomarin pharmaceutical says european commission approves brineura as first treatment for cln disease reuters   am et  european commission approves brineura™ cerliponase alfa the first treatment for cln disease a form of batten disease and ultrarare brain disorder in children pr newswire   am et  biomarin to attend upcoming investor conference pr newswire   am et  copyright – fmr llc  all rights reserved  terms of use privacy security site map  stock market research top stocks quotes  news  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas you are here stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries stock research center not a fidelity customer no problem try our research for free without opening an account   trending stocks market movers top rated by sector orders by fidelity customers filters refresh equity summary score provided by starmine investing insights technical events provided by recognia as of  methodology recognia methodology bullish and bearish events of the day provide longshort trading ideas by identifying us stocks that have recently formed a bullish or bearish classic chart pattern patterns must have taken at least  days to form which draws out the more significant patterns for intermediate or longterm trend direction the list is then filtered to include stocks with a minimum  for bullish and  for bearish close price and a minimum  trading volume most recent patterns are listed first patterns on the same date are sorted using recognias proprietary quantitative algorithm to draw strong companies to the top and if further sorting is required for stocks with the same quantitative analysis result it is done by trading volume to draw highest volume stocks to the top bofi log in for events hafc an earn epam sn log in for events chkp lho fit gts find out how to use fundamental analysis and technical analysis when evaluating stocks with the help of the fidelity learning center my research –  organize and track your favorite securities get started todays events as of  am et  earnings  dividends  splits  upgrades  downgrades  economic  upcoming webinar events visit the learning center events page for a full list of upcoming webinars the equity summary score is provided for informational purposes only does not constitute advice or guidance and is not an endorsement or recommendation for any particular security or trading strategy the equity summary score is provided by thomson reuters starmine an independent company not affiliated with fidelity investmentsgics® global industry classification standards is an industry classification system developed by standard  poors in collaboration with morgan stanley capital international msci sp uses gics to determine the market segment to which a company is assignednews commentary including related symbols and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their usestock markets especially foreign markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments sector funds can be more volatile because of their narrow concentration in a specific industrysystem availability and response times may be subject to market conditionsthe fidelity screeners are research tools provided to help selfdirected investors evaluate securities the criteria and inputs entered are at the sole discretion of the user and all screens or strategies with preselected criteria are solely for the convenience of the user information supplied or obtained from the screeners is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell securities or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy or approach to screening or evaluating stocks preferred securities exchange traded products or closed end funds fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their use determine which securities are right for you based on your investment objectives risk tolerance financial situation and other individual factors and reevaluate them on a periodic basis copyright – fmr llc  all rights reserved  terms of use privacy security site map  bmrn stock news  fidelity skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print  helpglossary helpglossary news  eventsbmrn biomarin pharmaceutical inc    as of pm et  quotes delayed at least  min log in for real time quote add to watch list set alert hypothetical trade option chain price history download to csv file download to excel file log in for more news expand all collapse all biomarin to host second quarter  financial results conference call and webcast on wednesday august  at pm et pr newswire –  pm et  san rafael calif dialin number us  canada dialin number international dialin number conference id  replay dialin number replay international dialin number conference id  briefsarepta and biomarin report execution of global settlement reuters –  am et  sarepta therapeutics inc srpt  sarepta therapeutics srpt and biomarin pharmaceutical inc announce execution of a global settlement and a license agreement resolving exon skipping patent litigation sarepta therapeutics and biomarin pharmaceutical inc announce execution of a global settlement and a license agreement resolving exon skipping patent litigation globenewswire –  am et  sarepta therapeutics inc srpt a us commercialstage biopharmaceutical company focused on the discovery and development of unique rnatargeted therapeutics for the treatment of rare neuromuscular diseases and biomarin pharmaceutical inc bmrn a leading biotechnology company in therapies for rare genetic diseases announced today that sarepta and biomarin executed a license agreement that provides s briefbiomarin pharmaceutical says plans to initiate phase  registrational study in q  for bmn  reuters –  am et  biomarin pharmaceutical inc bmrn  biomarins investigational gene therapy for hemophilia a at e vgkg dose maintains average factor viii levels within normal range for over one year  biomarin pharmaceutical inc bmrn says plans to initiate a phase  registrational study in q  for bmn  source text for eikon further company coverage biomarins investigational gene therapy for hemophilia a at e vgkg dose maintains average factor viii levels within normal range for over one year pr newswire –  am et  san rafael calif briefbiomarin submits pegvaliase biologics license application to the us fda for treatment of phenylketonuria reuters –  am et  biomarin pharmaceutical inc bmrn  biomarin submits pegvaliase biologics license application to the us fda for treatment of phenylketonuria  biomarin pharmaceutical inc bmrn  ‍company also intends to submit an application for registration in european union by year end ​ source text for eikon further company coverage biomarin submits pegvaliase biologics license application bla to the us fda for treatment of phenylketonuria pku pr newswire –  am et  san rafael calif we believe that pegvaliase offers the promise of an important new treatment option for those adult patients with pku unable to manage their condition with existing treatments technical research on biotech equities  celsion sarepta therapeutics biomarin pharma and contravir pharma pr newswire –  am et  new york june   if you want a stock review on clsn srpt bmrn or ctrv then come over to httpdailystocktrackercomregister and sign up for your free customized report today httpdailystocktrackercomregister celsion  on thursday shares in lawrenceville new jersey headquartered celsion corp clsn recorded a trading volume of  million shares which was higher than their three  biomarin announces acceptance of late breaking abstract at the international society on thrombosis and haemostasis  congress pr newswire –  am et  san rafael calif we feel privileged to be presenting the only human data in gene therapy for hemophilia a at isth said hank fuchs md president worldwide research and development at biomarin isth is a global notforprofit membership organization advancing the understanding prevention diagnosis and treatment of thrombotic and bleeding disorders briefbiomarin pharmaceutical says european commission approves brineura as first treatment for cln disease reuters –  am et  biomarin pharmaceutical inc bmrn  european commission approves brineura the first treatment for cln disease a form of batten disease and ultrarare brain disorder in children  biomarin pharmaceutical inc bmrn says dosing administration includes all ages from birth source text for eikon further company coverage european commission approves brineura™ cerliponase alfa the first treatment for cln disease a form of batten disease and ultrarare brain disorder in children pr newswire –  am et  san rafael calif on april   the committee for medicinal products for human use the scientific committee of the european medicines agency adopted a positive opinion for the companys marketing authorization application for brineuratm following an accelerated review procedure reserved for medicinal products expected to be of major public health interest biomarin to attend upcoming investor conference pr newswire –  am et  san rafael calif about biomarin biomarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and lifethreatening rare disorders for additional information please visit wwwbiomarincom information on biomarins website is not incorporated by reference into this press release biotech stocks on investors radar  biomarin pharma eyegate pharma navidea biopharma and cellectar biosciences pr newswire –  am et  new york may   this morning stockcallerscom covers the performances of biomarin pharmaceutical inc bmrn eyegate pharmaceuticals inc eyeg navidea biopharmaceuticals inc navb and cellectar biosciences inc clrb according to a report on investors business daily spdr sp biotech rose more than  in the first three months of  httpstockcallerscomregistration briefbiomarin q gaap loss per share  reuters –  pm et  biomarin pharmaceutical inc bmrn  biomarin announces first quarter  financial results  q gaap loss per share   q earnings per share view   thomson reuters ibes  q revenue  million versus ibes view  million biomarin announces first quarter  financial results pr newswire –  pm et  san rafael calif financial highlights biomarin pharmaceutical inc bmrn today announced financial results for the first quarter ended march   for the quarter ended march   gaap net loss was  million or  per basic and diluted share compared to gaap net loss of  million or  per basic and diluted share for the quarter ended march   biomarin to attend two upcoming investor conferences pr newswire –  am et  san rafael calif about biomarin biomarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and lifethreatening rare disorders for additional information please visit wwwbiomarincom information on biomarins website is not incorporated by reference into this press release biomarin sets high price for rare pediatric brain disease drug reuters –  pm et  biomarin pharmaceuticals inc said the annual price for its drug which won us approval on thursday to treat a rare and fatal type of pediatric brain disease is expected to be  after mandatory government discounts and rebates briefbiomarin says brineura us annual price  reuters –  pm et  biomarin pharmaceutical inc bmrn  biomarin pharmaceuticals says expects to begin shipping just approved brineura within  weeks  biomarin says expected annual cost for brineura to be  for ultrarare pediatric brain disease  biomarin says will have copay program to assist with outofpocket cost of brineura source text for eikon further company coverage us fda approves biomarins batten disease drug reuters –  pm et  the united states food and drug administration said on thursday it had approved biomarin pharmaceutical incs bmrn drug to treat a type of batten disease a rare disorder that mainly affects the nervous system and is ultimately fatal the drug brineura is an enzyme replacement therapy designed to slow loss of walking ability in patients three years or older with cln disease fda approves brineura™ cerliponase alfa for the treatment of cln disease a form of batten disease and ultrarare pediatric brain disorder in children pr newswire –  pm et  san rafael calif cln disease is an ultrarare rapidly progressive fatal brain condition which affects less than one in one million us residents many of whom are undiagnosed in clinical trials brineura an enzyme replacement therapy was shown to slow the loss of ambulation in symptomatic pediatric patients  years of age and older with cln disease page page   next  todays and upcoming events aug  bmrn to announce q earnings after market confirmed aug  bmrn earnings conference call at  pm listen past events last  days jun  shareholders meeting data provided by wall street horizon inc   technical events classic patterns past  days provided by recognia inc log in for trading events view all technical analysis in advanced chart technical analysis provided by trading central log in for trading events as with all your investments through fidelity you must make your own determination whether an investment is appropriate for you fidelity is not recommending or endorsing this security by making it available to customers you should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase before investing you should read the prospectus offering circular indenture or similar document carefully for a full description of the product including its features and risks to determine whether it is an appropriate investment for your investment objectives risk tolerance financial situation and other individual factors and be sure to reevaluate those factors on a periodic basisperformance data shown represents past performance which is no guarantee of future results current performance may be higher or lower than the performance data quoted yield and return will vary therefore you may have a gain or loss when you sell your sharesstock markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments growth stocks can be more volatile than other types of stocks value stocks can continue to be undervalued by the market for long periods of time foreign securities are subject to interestrate currencyexchangerate economic and political risks all of which are magnified in emerging markets illiquidity is an inherent risk associated with investing in real estate and reits there is no guarantee the issuer of a reit will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid closedend funds can trade at a discount to their nav shareholders of master limited partnerships may be treated as partners for tax purposes partnerships issue a schedule k form  rather than a form  form for tax purposes it lists the partners share of income deductions credits etc speak with your tax advisor to determine how this may affect you a royalty trust is a type of corporation mostly in the united states or canada usually involved in oil and gas production or mining royalty trusts may have special tax treatment so you should consult a tax advisor on the potential tax consequences of investing in themnews commentary and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their useany data charts and other information provided on this page are intended for research purposes to help selfdirected investors evaluate many types of securities including but not limited to common stocks american depository receipts master limited partnerships real estate investment trusts traditional preferred stock trust preferred securities thirdparty trust certificates convertible securities mandatory convertible securities and other exchangetraded equity andor debt securities criteria and inputs entered including the choice to make security comparisons are at the sole discretion of the user and are solely for the convenience of the user analyst opinions ratings and reports are provided by thirdparties unaffiliated with fidelity all information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell a security or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating individual securities fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from its use copyright – fmr llc  all rights reserved  terms of use privacy security site map  see the latest features personalizedget relevant information about your holdings right when you need itsee your performance click the portfolio icon to get information about stocks you own without leaving the research pagefaster access to positions a shortcut to view the full list of positions in your portfolio yes please use the ticker search boxadd your own notes use notebook to save your investment ideas in one convenient private and secure place convenient for youresearch thats clear accessible and all in one place makes for a better experienceonestop shop see everything you need to make investment decisions right in the dashboardaccess anywhere no matter where you are use the stock research experience across multiple devicesnew ideas on the ready find new ideas using quick links to the stock screener new ways to researchdiscover new tools to add or diversify your existing research strategystocktwits read live tweets from the financial and investing community about the stock youre interested infundamental analysis save time on research by getting an overall assessment of a companys valuation quality growth stability and financial healthrecognia technical analysis perfect for the technical trader—this indicator captures a stocks technical events and converts them into short medium and longterm sentimenttop competitors see how a stock measures up by instantly comparing it to the industry average and its top four competitorssocial sentiment get a sense of peoples overall feelings towards a company in social media with this summary toolearnings data monitor earnings expectations over the past three quarters and model a stocks price based on its pe henry j fuchs  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors henry j fuchs check out list of companies and businesses related to henry j fuchs find out henry j fuchs address and contact details view other people related to henry j fuchs  coworkers colleagues companions etc address  e bayshore rd suite  palo alto  ca companies related to henry j fuchs cikcompany namepositioncompany addressbiomarin pharmaceutical incpresident worldwide rd  digital drive novato ardea biosciences incdepresident  ceo  directors place san diego genomic health incdirector  penobscot drive redwood city mirati therapeutics incdirector  towne centre drive suite  san diego  henry j fuchs on the web persons related to henry j fuchs  biomarin pharmaceutical incnamepositioncityjeffrey robert ajerevp chief commercial officer novatojeffrey robert ajersvp chief commercial of san rafaelsteve aselagesvp global commercial dev novatosteve aselagesvp chief business officer novatorobert baffievp technical operations novatorobert baffisvp technical operations novatorobert baffievp technical operations novatorobert baffievp technical operations san rafaelkenneth batedirector cambridgekenneth batedirector novatojean jacques bienaimechief executive officer jean jacques bienaimechief executive officer novatojean jacques bienaimechief executive officer novatojean jacques bienaimechief executive officer palo altojean jacques bienaimechief executive officer san rafaeljean jacques bienaimechief executive officer novatojean jacques bienaimechief executive officer novatojeffrey h cooperchief financial officer novatojeffrey h coopersvp chief financial officer novatojeffrey h coopersvp chief financial officer novatojeffrey h coopersvp chief financial officer novatofranz l cristianidirector novatofranz l cristianidirector novatogeorge eric davisevp general counsel novatogeorge eric davisvp general counsel novatogeorge eric davisvp general counsel novatogeorge eric davisnovatogeorge eric davissvp general counsel san rafaelwillard h deredirector thousand oakslouis drapeauchief executive officer novatolouis drapeauchief executive officer novatokathryn e falbergdirector rockvillehenry j fuchspresident worldwide rd palo altohenry j fuchsevp chief medical officer novatohenry j fuchsevp chief medical officer san rafaelmichael g greydirector michael g greydirector novatomichael g greydirector novatomichael g greydirector novatoelaine j herondirector novatoelaine j herondirector novatoelaine j herondirector  digital driveelaine j herondirector novatoemil d kakkissvp business operations novatoemil d kakkischief medical officer novatoemil d kakkissvp chief medical officer novatoemil d kakkischief medical officer novatojoseph klein iiidirector novatojoseph klein iiidirector novatojeffrey landausvp administration novatojeffrey landausvp administration novatopierre lapalmedirector novatopierre lapalmedirector novatopierre lapalmedirector novatopierre lapalmedirector novatov bryan lawlisdirector haywardv bryan lawlisdirector novatoalan lewisdirector san diegoalan lewisdirector novatorichard a meierdirector santa anarichard a meierdirector novatorichard a meierdirector santa anabrian muellersvp corporate controller novatobrian muellervp corporate controller novatofredric d pricechief executive officer novatodavid e i pyottdirector erich sagerdirector novatoerich sagerdirector novatodennis slamondirector san rafaeldaniel k spiegelmanevp chief financial officer palo altodaniel k spiegelmanevp chief financial officer novatodaniel k spiegelmanevp chief financial officer san rafaelchristopher m starrsvp chief scientific officer novatochristopher m starrsvp chief scientific officer novatochristopher m starrsvp chief scientific officer novatostuart j swiedlernovatostuart j swiedlersvp clinical affairs novatostuart j swiedlersvp clinical affairs novatojohn urquhartcaryjohn urquhartdirector john urquhartdirector novatojohn urquhartnovatogwynn williamsdirector gwynn williamsdirector novatomark woodvp human resources novatomark woodvp human resources novatomark woodvp human resources novatomark woodvp human resources novatomark woodvp human resources novatowilliam d youngdirector south san franciscowilliam d youngdirector novatopersons related to henry j fuchs  ardea biosciences incdenamepositioncity capital gp llc owner new york capital gp llcdirector new york capital gp llc owner new york capital gp llc owner new york capital gp llcdirector new yorkdetlef albrechtsvp  chief medical officer palo altodane andreeff owner baton rougedane andreeff owner baton rougeusha arunachalamvp business development palo altoplc astrazenecalondonbaker biotech capital gp llc owner new yorkbaker biotech capital gp llc owner new yorkbaker biotech capital gp llc owner new yorkbaker biotech capital ii gp llc owner new yorkbaker biotech capital ii gp llc owner new yorkbaker biotech capital ii gp llcnew yorkbaker biotech capital ii z gp llc owner new yorkbaker biotech capital ii z gp llcnew yorkbaker biotech capital ii z gp llc owner new yorkbaker biotech capital iii gp llc owner new yorkbaker biotech capital iii gp llc owner new yorkbaker biotech capital iii z gp llc owner new yorkbaker biotech capital iii z gp llc owner new yorkbaker bros advisors llcnew yorkbaker bros capital gp llc owner new yorkbaker bros capital gp llc owner new yorkbaker bros capital gp llc owner new yorkbaker bros capital gp llcdirector new yorkbaker brothers life sciences capital gp llc owner new yorkbaker brothers life sciences capital gp llcdirector new yorkbaker brothers life sciences capital gp llcdirector new yorkfelix bakerfelix bakerdirector new yorkfelix bakernew yorkfelix bakerdirector new yorkjulian bakerjulian bakernew yorkjulian bakernew yorkjulian bakernew yorkjulian bakernew yorkbaker tisch capital gp llc owner new yorkbaker  tisch capital gp llc owner new yorkjohn w beckdirector carlsbadjohn w beckdirector carlsbadjohn w becksvp finance  operations cfo san diegostephen davisevp  coo san diegohicky denislafayettewendy l dixondirector san diegohenry j fuchspresident  ceo palo altohenry j fuchsdirector lafayettehenry j fuchsdirector carlsbadhenry j fuchsdirector carlsbadhenry j fuchsdirector san diegodavid t hagertysenior vp  cmo san diegodenis hickeychief financial officer lafayettedenis hickeychief financial officer carlsbadzhi hongexecutive vp research lafayettejerry t jacksondirector palo altocraig a johnsondirector san diegokellogg capital group llcnew yorkkellogg capital group llc owner new yorksteven b ketchumsenior vp operations palo altosteven b ketchumpalo altochristopher w kruegersr vp chief business officer carlsbadchristopher w kruegersr v p cbo and secretary carlsbadchristopher w kruegersvp  cbo san diegogary a lyonsdirector palo altokimberly manhardsr vp reg affairs  operations lafayettekimberly manhardsr vp reg affairs  ops carlsbadkimberly manhardsr vp reg affairs  operations carlsbadkimberly manhardsvp regulatory  dev ops san diegoernest mariodirector palo altopatrick m oconnorsr vp r  preclindev cso carlsbadmark l perrydirector palo altojohn poyhonendirector carlsbadjohn poyhonendirector carlsbadjohn poyhonendirector san diegobarry d quartpresident ceo and secretary lafayettebarry d quartpresident and ceo carlsbadbarry d quartpresident and ceo san diegojack remingtondirector palo altojack remingtondirector lafayettejack remingtondirector carlsbadjack remingtondirector carlsbadjack remingtondirector san diegogregory w schaferpalo altokathleen staffordprincipal financial officer palo altotang capital management llcsan diegotang capital management llcsan diegotang capital partners lpsan diegotang capital partners lpsan diegokevin c tangdirector san diegokevin c tangdirector san diegokevin c tangdirector san diegooscar tangnew yorkoscar tangnew yorkdavid tuckerprincipal financial officer palo altopersons related to henry j fuchs  genomic health incnamepositioncity capital gp llcdirector new york capital gp llcdirector new york capital gp llcdirector new york lpnew york lpnew yorkbrian g atwoodmenlo parkbaker biotech capital gp llcdirector new yorkbaker biotech capital gp llcdirector new yorkbaker biotech capital gp llc owner new yorkbaker biotech capital gp llcdirector new yorkbaker biotech capital ii gp llc owner new yorkbaker biotech capital ii z gp llc owner new yorkbaker biotech capital iii gp llc owner new yorkbaker biotech capital iii z gp llc owner new yorkbaker bros advisors gp llcnew yorkbaker bros advisors llcdirector new yorkbaker bros advisors llcnew yorkbaker bros advisors lpnew yorkbaker bros capital gp llc owner new yorkbaker bros capital gp llcdirector new yorkbaker bros capital gp llcdirector new yorkbaker bros investments ii lpnew yorkbaker bros investments lpnew yorkbaker brothers life sciences capital gp llcdirector new yorkbaker brothers life sciences capital gp llcdirector new yorkbaker brothers life sciences capital gp llcdirector new yorkbaker brothers life sciences lpnew yorkfelix bakerdirector felix bakerdirector new yorkfelix bakernew yorkfelix bakernew yorkfelix bakerdirector new yorkjoffre bakerchief scientific officer redwood cityjulian bakerjulian bakerdirector new yorkjulian bakernew yorkjulian bakerdirector new yorkjulian bakerdirector new yorkjulian bakerdirector new yorkjulian bakerdirector new yorkjulian bakernew yorkbaker  tisch capital gp llc owner new yorkbaker  tisch capital gp llcdirector new yorkbakertisch investments lpnew yorkbrook h byersdirector menlo parkbrook h byersdirector menlo parkbrook h byersdirector menlo parkbrook h byersdirector menlo parkfred e cohendirector san franciscofred e cohendirector san franciscofred e cohendirector san franciscofred e cohendirector san franciscog bradley colecoo redwood citysamuel d colelladirector menlo parksamuel d colelladirector menlo parksamuel d colelladirector menlo parksamuel d colelladirector menlo parkassociates fbbnew yorkphillip g febbochief medical officer redwood cityhenry j fuchsdirector palo altohenry j fuchsdirector novatomichael d goldbergdirector menlo parkmichael d goldbergdirector menlo parkmichael d goldbergdirector menlo parkmichael d goldbergdirector menlo parkginger l grahamdirector ginger l grahamdirector redwood cityginger l grahamdirector boulderkathy l hibbssvp  general counsel redwood cityross a md jaffemenlo parkkleiner perkins caufield  byers x a lp owner menlo parkkleiner perkins caufield  byers x b lp owner menlo parkkpcb x associates llc owner menlo parklaura leberchief communication officer redwood citywilliam j phd linkmenlo parkrandall s livingstondirector stanfordrandall s livingstondirector stanfordrandall s livingstondirector stanfordbarbara n lubashmenlo parkkim mceachronchief people officer redwood citydonald b mildermenlo parkwoodrow a myers jrdirector redwood citywoodrow a myers jrdirector thousand oakswoodrow a myers jrdirector woodland hillswoodrow a myers jrdirector indianapolisgeoffrey m parkerdirector carlsbadfrederic plachief bus  prod dev officer redwood citykimberly j popovitspresident and ceo redwood citykimberly j popovitspresident and ceo redwood cityjason w radfordchief legal officer redwood cityrebecca b robertson owner menlo parkdean l schornocfo redwood cityrandal w scottchief executive officer redwood cityrandal w scottceo invitae corporation redwood citysteven shakchief scientific officer redwood citytarrant advisors incsan fransicotarrant advisors inc owner san franciscojames j vaughnchief commercial officer redwood cityversant affiliates fund ia lpmenlo parkversant affiliates fund ib lpmenlo parkversant side fund i lpmenlo parkversant venture capital i lp owner menlo parkversant ventures i llcmenlo parkpersons related to henry j fuchs  mirati therapeutics incnamepositioncity lpnew yorkbaker bros advisors gp llcnew yorkbaker bros advisors llc owner new yorkbaker bros advisors lp owner new yorkbaker brothers life sciences lpnew yorkfelix bakerfelix baker owner new yorkjulian bakerjulian bakernew yorkcharles m baumpresident  ceo san diegoberkley capital management ltd owner new providenceboxer asset management inc owner new providenceboxer asset management incnew providenceboxer capital llc owner del marboxer capital llc owner solana beachbraslyn ltd owner new providencebruce l a carterdirector seattleisan chensr vp chief medical san diegojamie christensensvp chief science officer san diegoaaron i davissolana beachshehan bharatha dissanayakesolana beachjamie a donadiosr vp cfo san diegohenry j fuchsdirector palo altohenry j fuchsdirector san diegochristopher fuglesangsolana beachmark j gergenexecutive vp coo san diegomark j gergenexec vp and coo san diegomartin godboutdirector san diegomichael g greydirector michael g greydirector san diegopeter evan harwinsolana beachrachel humphreysan diegosamuel d isalynew yorkcraig a johnsondirector la jollacraig a johnsondirector san diegorodney w lappedirector san diegochristopher c lemastersevp chief business officer san diegojoseph lewisjoseph lewisnew providenceivan m lieberburglos angelesmva investors llcdel marmva investors llcsolana beachmva investors llcnew providenceorbimed advisors llc owner new yorkorbimed capital gp iv llcnew yorkneil reismandirector solana beachwilliam r ringodirector william r ringodirector san diegotang capital management llcsan diegotang capital management llcsan diegotang capital partners lpsan diegotang capital partners lp owner san diegokevin c tangsan diegokevin c tangsan diegopeter a thompsonsan diegowilliam n harwin  gift trust fbo peter harwinsolana beach page not found  leadership directories products blogs about client support order return home     contact us toll free   broadway suite  new york ny  tel       fax    k street nw suite  washington dc  tel         fax   terms of use  privacy policy  faq  contact us  leadership directories inc